Podcast III: Evaluate the Role of Currently Available Antifibrotic Agents in the Treatment of IPF and SSc-ILD
August 26, 2019
August 26, 2020
Critical Care, Emergency Medicine, Geriatric Medicine, Hospitalist, Pathology, Pharmacy, Pulmonology, Radiology, Rheumatology
Jointly Provided by AKH, Inc. and peerXchange, Inc.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Scroll to the Bottom of this Information to Begin this Course
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
- Physician Assistants — NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
All other health care professionals completing this course will be issued a statement of participation.
This curriculum is designed to meet the educational needs of pulmonologists, internists, rheumatologists, primary care physicians, nurse practitioners, and physician assistants who provide care to patients with idiopathic pulmonary fibrosis and systemic sclerosis-interstitial lung disease.
The management of progressing fibrotic pulmonary disease continues to evolve and guidelines are challenged to stay abreast of, and to reflect, advances from recent clinical studies or drug approvals. Clinicians need to be aware of this challenging landscape to develop treatment plans that are current and that help patients to achieve optimal outcomes. In this podcast, Drs. Zibrak and Saketkoo will review the evidence supporting the use of antifibrotic agents, specifically nintedanib and pirfenidone in patients with IPF and the emerging evidence that these drugs may be useful in SSc-ILD.
- What is the role of currently approved antifibrotics in the treatment of PF-ILD?
- What is the current status of antifibrotics?
- Which patients with reduced lung function might be considered for treatment with antifibrotic therapy?
- What is the current thinking with managing side effects associated with antifibrotic therapy?
- Are there shared perspectives on treatment among rheumatology and pulmonary ILD specialists?
Upon completion of this activity, participants should be better able to:
- Evaluate the role of currently available antifibrotic agents in the treatment of patients with pulmonary fibrosis associated with IPF and SSc-ILD.
Joseph D. Zibrak, MD
Associate Professor of Medicine
Harvard Medical School
Director, ILD Center
Division of Pulmonology and Critical Care
Beth Israel Deaconess Medical Center
Lesley Anne Saketkoo, MD, MPH
Associate Professor of Medicine
Tulane University School of Medicine
Clinical Immunology, Allergy and Rheumatology, Pulmonary Diseases, Critical Care and Environmental Medicine
Director, New Orleans Scleroderma & Sarcoidosis Patient Care & Research Center
Co-Director, UMC Comprehensive Pulmonary Hypertension Center
New Orleans, LA
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and peerXchange, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
Physician Assistants: NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of .5 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Disclosures of Conflicts of Interest
It is the policy of AKH Inc. and peerXchange, Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.
Joseph D. Zibrak, MD
Dr. Zibrak receives consulting fees from Boehringer Ingelheim, Genentech, and Hoffman LaRoche and participates on the Speakers Bureau for Boehringer Ingelheim and Genentech.
Lesley Anne Saketkoo, MD, MPH
Dr. Saketkoo has nothing to disclose.
Deborah Dean, President: has disclosed no financial relationships.
Wendy Gloffke, PhD: has disclosed no financial relationships.
AKH Staff and Reviewers Disclosures
Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner/Reviewer: has disclosed no financial relationships.
Patricia Brignoni, AKH Director of Operations/Reviewer: has disclosed no financial relationships.
Method of Participation
There are no fees for participating and receiving CME credit for this enduring activity. During the period August 26, 2019 through August 26, 2020, participants must 1) read the CME information, including learning objectives and facul¬ty disclosures; 2) study the educational activity; and 3) complete the pre-test, post-test and evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, submit and your post-test will automatically be graded. Once you successfully complete the post-test (score of 70% or greater) and activity evaluation, your Statement of Credit will be made available immediately to view or print for your records.
Course Viewing Requirements
This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.
Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and peerXchange, Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
© 2019. This CME activity is held as copyrighted © by peerXchange, Inc. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
If you have any questions regarding CME or relating to the accreditation of this activity, please contact AKH at email@example.com
Continuing Medical Education and Continuing Education
When you register for a Continuing Medical Education (CME) or a Continuing Education (CE) activity through one of our Web sites, we collect certain personally identifiable information from you such as your name, email address and mailing address. If you are a pharmacist and wish to receive CE credit, you are also required to provide your NAPB # and month and day of birth. For more information about NABP and CPE Monitor click here. In addition to personally identifiable information, we collect aggregated non-personally identifiable information about the activities undertaken by our users. We use the information that we collect through CME/CE activities in several ways:
- We work with several accredited companies who are accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. As a Joint-Provider, we are required periodically to submit aggregated data about CME participants and the CME activities we certify. We also provide personally identifiable information to other accredited CME/CE providers who certify CME/CE activities posted on our Web sites, as required by the ACCME and other accrediting bodies. These reports may include personally identifiable information about you and credits issued to you, for the purpose of maintaining records that you can request from the accredited provider for up to six (6) years;
- Commercial supporters of CME/CE activities on our Web site will receive only aggregated data about CME/CE activities that are relevant to their interests and/or the courses they support;
- Our Editorial and Customer Support Staff will have internal access to files containing personally identifiable information, including evaluation forms and aggregated CME /CE participant information. These files can be accessed in order to respond to your questions or comments. Our staff may also use personally identifiable information, including registration information and evaluation data, in assessing educational needs and planning marketing activities.